April 2014, 22:3

03 December 2014

Original Paper

Original Paper

Heparin has No Place as an Anticoagulant in PCI – A Protagonist’s View

Tan Huay Cheem

ASEAN Heart Journal

First online: 

  • Facebook Social Icon
  • Twitter Social Icon
  • Google+ Social Icon

Reference Tools

Abstract

Unfractionated heparin is the standard anticoagulant of choice for patients undergoing percutaneous coronary intervention. However it has signifi cant pharmacologic limitations such as need for frequent laboratory monitoring of anticoagulation status and unpredictable response in acute infl ammatory states. Low molecular weight heparin such as enoxaparin has emerged as a feasible alternative with clinical studies of its use in both elective and emergency PCI indicating that it is just as effective, and has higher safety profi le. With its more predictable anticoagulant response, greater bioavailability, practical clinical benefi ts including early sheath removal; and potential cost saving, enoxaparin has made itself a preferred alternative in modern PCI.

Key words:

Enoxaparin - Activate Clotting Time - Major Bleeding Event - Urgent Revascularization - Enoxaparin Group

 

____________________________________________________________________________________________

 

​​

Correspondence to Tan Huay Cheem, Director, National University Heart Centre, Singapore; Associate Professor, Yong Loo Lin School of Medicine, National University of Singapore.

Telephone: (+65) 6772 5596. Fax: (+65) 6872 2998. E-mail: huay_cheem_tan@nuhs.edu.sg

Open Access: This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

.

Tel No: +603-7931 7900
Fax No: +603-7932 1400

 

 

D-13A-06, Menara Suezcap 1, KL Gateway,
No.2 Jalan Kerinchi, Gerbang Kerinchi Lestari,
59200 Kuala Lumpur, Malaysia.

www.aseancardiology.org

ASEAN HEART Journal is Supported by Unrestricted Grant From 

Committed to therapeutic advances in cardiovascular research